• Skip to main content
  • Skip to primary sidebar

Biotech Briefings

  • Home
  • About
  • Editors
  • Topics
  • Subscribe
  • Home
  • About
  • Editors
  • Topics
  • Subscribe
Avatar

David A. Wolber

,

dwolber@gibsondunn.com

View Full Profile

Recent China Actions Elevate Conflicts of Law Risks for Global Companies; Trump-Xi Summit Signals Hope for “Détente” in Some Areas

May 19, 2026 | Posted by David A. Wolber; Adam M. Smith; Topic(s): Government Regulation; International Trade; Trends and Insights

Despite recent high-level U.S.-China talks, several recent developments in China have elevated international trade-related compliance risks and challenges for companies with commercial ties to mainland China or dealings with Chinese counterparties.  While it is unclear the extent to which these developments move the needle in terms of practical legal and enforcement implications in China, there is little doubt Beijing is sending a clear message that it is elevating the tone and seriousness of the counter-threat against companies deemed to be complicit in implementing foreign sanctions and other measures affecting Chinese companies.

Read More

Primary Sidebar

Read our Life Sciences 2026 Outlook here.
Read our 2026 Royalty Finance Market Update here.

Topics

Antitrust

Capital Markets

Clinical Trials

CVR Spinoff

CVRs

Delaware Law

ECVC

False Claims Act

FDA

FDA Guidance

Government Regulation

International Trade

IPOs

License Agreements

M&A

Manufacturing

Reverse Mergers

Royalty Finance

SEC Disclosure

SEC Updates

Securities Litigation

Shareholder Activism

Tax

Trends and Insights

Editors

David A. Wolber

Rachel E. Baron

Branden C. Berns

Aaron K. Briggs

Jina L. Choi

Matt Donnelly

Pamela Lawrence Endreny

Gustav W. Eyler

Hui Fang

Carlo Felizardo

Mark Goldman

Bree Gong

Charlotte Jacobsen

Candice D. Johnson

Jin Hee Kim

Zaneta J. Kim

Wynne Leahy

Nicholas G. Linke

Jeff Lombard

Jane M. Love, Ph.D.

Mary Beth Maloney

Katlin McKelvie

Ryan A. Murr

Melanie E. Neary

John D.W. Partridge

Lindsay M. Paulin

Michael J. Perry

Jonathan M. Phillips

Ryan Rott

Lindsey D. Schmidt

Samantha Sewall

Sam Shapiro

Evan Shepherd

Eric B. Sloan

Adam M. Smith

Bradley P. Smith

Karen A. Spindler

Eric J. Stock

Ayushi Sutaria

Terrell Ussing

Jessica Valenzuela

Stephen Weissman

Kamia Williams

Useful Links

  • Gibson Dunn Website
  • Gibson Dunn Life Sciences Landing page
  • Securities Regulation and Corporate Governance Monitor
  • NVCA Model Legal Documents
  • Royalty Finance Tracker
  • Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024
  • IPO Resource Center
  • IP Disputes and Litigation

Archives

Subscribe to Updates
RSS Feed
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved.